Continue reading Closing Bell: A great day that may feel empty (AA, PEP, VG, LEN, RPRX, PLUG, MMM, WFC)

Closing Bell: A great day that may feel empty (AA, PEP, VG, LEN, RPRX, PLUG, MMM, WFC) originally appeared on BloggingStocks on Thu, 08 Oct 2009 16:00:00 EST. Please see our terms for use of feeds.

Continue reading Closing Bell: Mixing the indexes (AAI, COP, RPRX, VG, SIRI)

Closing Bell: Mixing the indexes (AAI, COP, RPRX, VG, SIRI) originally appeared on BloggingStocks on Wed, 07 Oct 2009 16:00:00 EST. Please see our terms for use of feeds.

Here are some highlights from last week's earnings coverage from BloggingStocks:

• Aeropostale Inc. (NYSE: ARO) strong Q2 results beat expectations due to rising same-store sales.
• Agilent Technologies Inc. (NYSE: A) Q3 earnings topped low expectations and revenue declined.
• Analog Devices Inc. (NYSE: ADI) posted better-than-expected Q3 results but shares fell on weaker margins.
• Baidu Inc. (NASDAQ: BIDU) CEO said its new advertising efforts will boost sales over the long run.
• Barnes & Noble Inc. (NYSE: BKS) had a better-than-expected Q2 profit but same-store sales fell.
• BJ's Wholesale Club Inc. (NYSE: BJ) reported solid Q2 numbers and raised its full-year guidance.

Continue reading Earnings highlights: B&N, Deere, Heinz, Home Depot, HP, Sears, Target ...

Earnings highlights: B&N, Deere, Heinz, Home Depot, HP, Sears, Target ... originally appeared on BloggingStocks on Sat, 22 Aug 2009 12:10:00 EST. Please see our terms for use of feeds.

Repros Therapeutics (NASDAQ: RPRX) easily takes the prize for most dismal earnings report of the day. Not only did the drug firm report a wider-than-forecast second-quarter loss, it also warned that bankruptcy is a real possibility unless the company can secure significant additional capital.

Specifically, Repros confessed to a second-quarter net loss of $8.9 million, or 59 cents per share, compared to Wall Street's consensus estimate for a loss of 46 cents per share. The company chalked up its poor results to a 16% annualized increase in clinical development activities for Proellex -- which has been placed on clinical hold by the FDA -- as well as a 60% year-over-year jump in general and administration expenses.

Continue reading Cash-strapped Repros Therapeutics warns of potential bankruptcy

Cash-strapped Repros Therapeutics warns of potential bankruptcy originally appeared on BloggingStocks on Mon, 17 Aug 2009 11:40:00 EST. Please see our terms for use of feeds.